PMA device
Allurion Gastric Balloon System
Allurion Technologies, Inc. · Implant, Intragastric For Morbid Obesity (LTI, Class III) · First FDA decision Feb 20, 2026, newest Sep 23, 2026Obesity
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
4
Naming "Allurion Gastric"
MAUDE reports
0
Brand "Allurion Gastric", since 2015
PubMed studies
1
Mentioning "Allurion Gastric"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Allurion Gastric Balloon System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Allurion Gastric Balloon SystemPMA supplement
P250023-S002 · Decided Sep 23, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
P250023 · Decided Feb 20, 2026 · 235 days after receipt
Device type: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY (LTI) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Bariatric Surgery for the Treatment of Morbid Obesity - Facility Certification RequirementNational analysisReview closedCAG-00250R3Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250R2Updated Sep 16, 2026
- Bariatric Surgery for the Treatment of Morbid ObesityNational analysisReview closedCAG-00250RUpdated Sep 16, 2026
- Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid ObesityNational determinationOn the books100.1Updated Apr 9, 2025
- Bariatric Surgical Management of Morbid ObesityLocal determinationIn effectL35022Novitas Solutions, Inc.Updated May 7, 2021
- Surgical Management of Morbid ObesityLocal determinationIn effectL33411First Coast Service Options, Inc.Updated Oct 2, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Allurion Gastric", any status and sponsor, newest update first.
- Allurion Gastric Balloon PASNot yet recruiting
Allurion TechnologiesNot on our public-company list
NCT07684664 · 250 participants (planned) · Start Jul 15, 2026 · Primary completion Feb 19, 2029
Device: Active Elipse Device · For: Obesity (BMI>30); Obesity & Overweight
- The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)Pivotal-lookingActive, not recruiting
Allurion TechnologiesNot on our public-company list
NCT05368259 · 1,000 participants (planned) · Start May 12, 2022 · Primary completion Nov 1, 2024
Device: AGBS · For: Obesity
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 17 sites in all
Cleveland Clinic LondonAcademic, hospital or other
NCT06305208 · 300 participants (planned) · Start Feb 1, 2024 · Primary completion Feb 1, 2034
Device: Endoscopic gastric suturing; Endoscopic gastric plication and 4 more · For: Obesity; Diabetes Mellitus, Type 2
Sites: London, United Kingdom
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Allurion Gastric", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LTI
5,233 reports: 2,779 malfunction, 2,372 injury, 70 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Allurion Gastric"[tiab]. The summary above synthesizes these.
- Evaluation of the Efficacy and Safety of the Allurion® Gastric Balloon in 300 Patients from a Single Metabolic Center in Ecuador : Gastric Balloon in Ecuador - Efficacy & Safety.
Tinoco Ortiz T, Torres Guaicha M, Tobar A, et al. · Obes Surg · 2026
Other devices of this type
Also filed under product code LTI.
- Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2023
- Obalon Balloon SystemMedtimo, Inc. · PMA 2022
- Orbera Intragastric BalloonBoston Scientific Corporation · PMA 2026
- Bioenterics Lap-Band Adjustable Gastric Banding SystemMedtimo, Inc. · PMA 2003
- ReShape Integrated Dual Balloon SystemBoston Scientific Corporation · PMA 2018
- Spatz3 Adjustable Balloon SystemSpatz Fgia, Inc. · PMA 2023
- Ethicon Endo-Surgery Curved Adjustable Gastric with Sutureless Port and ApplierObtech Medical GmbH · PMA 2016
- Realize Adjustable Gastric BandObtech Medical GmbH · PMA 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.